Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Deborah Schrag, M.D.

TitleAssociate Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana Farber Cancer Institute
Smith Bldg 204
44 Binney St
Boston MA 02115
Phone617/582-8301
Fax617/582-7450

 Mentoring 
 current student opportunities
Available: 09/17/12, Expires: 07/01/14

Seeking HMS students to work on series of projects that involve studying trends in state specific Medicaid policies and how they relate to population health metrics. Health metrics include adherence to prevention measures as well as cancer quality metrics. Students will learn to manipulate large data bases, learn econometric techniques and conduct policy oriented research. Students will participate in data analysis, interpretation and manuscript writing dependent on skill sets/interests and abilities.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Weeks JC, Mack JW, Schrag D. Talking with patients about dying. N Engl J Med. 2013 Jan 31; 368(5):480-1.
    View in: PubMed
  2. Chen AB, Cronin A, Weeks JC, Chrischilles EA, Malin J, Hayman JA, Schrag D. Palliative Radiation Therapy Practice in Patients With Metastatic Non-Small-Cell Lung Cancer: A Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol. 2013 Feb 10; 31(5):558-64.
    View in: PubMed
  3. McCleary NJ, Wigler D, Berry D, Sato K, Abrams T, Chan J, Enzinger P, Ng K, Wolpin B, Schrag D, Fuchs CS, Hurria A, Meyerhardt JA. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013; 18(1):64-72.
    View in: PubMed
  4. Elena JW, Travis LB, Simonds NI, Ambrosone CB, Ballard-Barbash R, Bhatia S, Cerhan JR, Hartge P, Heist RS, Kushi LH, Lash TL, Morton LM, Onel K, Pierce JP, Robison LL, Rowland JH, Schrag D, Sellers TA, Seminara D, Shu XO, Thomas NE, Ulrich CM, Freedman AN. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst. 2013 Jan 16; 105(2):85-94.
    View in: PubMed
  5. Sinclair AH, Schymura MJ, Boscoe FP, Yung RL, Chen K, Roohan P, Tai E, Schrag D. Measuring colorectal cancer care quality for the publicly insured in New York State. Cancer Med. 2012 Dec; 1(3):363-71.
    View in: PubMed
  6. Khrizman P, Niland JC, Ter Veer A, Milne D, Bullard Dunn K, Carson WE, Engstrom PF, Shibata S, Skibber JM, Weiser MR, Schrag D, Benson AB. Postoperative Adjuvant Chemotherapy Use in Patients With Stage II/III Rectal Cancer Treated With Neoadjuvant Therapy: A National Comprehensive Cancer Network Analysis. J Clin Oncol. 2013 Jan 1; 31(1):30-8.
    View in: PubMed
  7. Abel GA, Chen K, Taback N, Hassett MJ, Schrag D, Weeks JC. Impact of oncology-related direct-to-consumer advertising: Association with appropriate and inappropriate prescriptions. Cancer. 2013 Mar 1; 119(5):1065-72.
    View in: PubMed
  8. Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med. 2012 Nov 6; 157(9):611-20.
    View in: PubMed
  9. Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012 Oct 25; 367(17):1616-25.
    View in: PubMed
  10. Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, Hornick JL, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, Schrag D, Fuchs CS, Ogino S. Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies. Arch Surg. 2012 Aug; 147(8):715-23.
    View in: PubMed
  11. Yung RL, Hassett MJ, Chen K, Gesten FC, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, Schrag D. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1102-5.
    View in: PubMed
  12. Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231.
    View in: PubMed
  13. Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012 Jul 20; 30(21):2624-34.
    View in: PubMed
  14. Feuer EJ, Lee M, Mariotto AB, Cronin KA, Scoppa S, Penson DF, Hachey M, Cynkin L, Carter GA, Campbell D, Percy-Laurry A, Zou Z, Schrag D, Hankey BF. The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer. 2012 Nov 15; 118(22):5652-62.
    View in: PubMed
  15. Zhu J, Sharma DB, Gray SW, Chen AB, Weeks JC, Schrag D. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA. 2012 Apr 18; 307(15):1593-601.
    View in: PubMed
  16. Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, Aiello Bowles EJ, Schrag D. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist. 2012; 17(3):419-27.
    View in: PubMed
  17. Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. Cancer. 2012 Sep 1; 118(17):4309-20.
    View in: PubMed
  18. Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. 2012 Feb 8; 104(3):211-27.
    View in: PubMed
  19. Meyerhardt JA, Li L, Sanoff HK, Carpenter W, Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol. 2012 Feb 20; 30(6):608-15.
    View in: PubMed
  20. Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage. 2012 Feb; 43(2):205-17.
    View in: PubMed
  21. Weiser MR, Gönen M, Chou JF, Kattan MW, Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol. 2011 Dec 20; 29(36):4796-802.
    View in: PubMed
  22. Elkin EB, Snow JG, Leoce NM, Atoria CL, Schrag D. Mammography capacity and appointment wait times: barriers to breast cancer screening. Cancer Causes Control. 2012 Jan; 23(1):45-50.
    View in: PubMed
  23. Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gönen M, Schrag D, Basch E. Reliability of adverse symptom event reporting by clinicians. Qual Life Res. 2012 Sep; 21(7):1159-64.
    View in: PubMed
  24. Zafar SY, Malin JL, Grambow SC, Abbott DH, Schrag D, Kolimaga JT, Zullig LL, Weeks JC, Fouad MN, Ayanian JZ, Wallace R, Kahn KL, Ganz PA, Catalano P, West DW, Provenzale D. Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. BMC Cancer. 2011; 11:354.
    View in: PubMed
  25. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, Ajani JA. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30.
    View in: PubMed
  26. Abrams TA, Brightly R, Mao J, Kirkner G, Meyerhardt JA, Schrag D, Fuchs CS. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol. 2011 Aug 20; 29(24):3255-62.
    View in: PubMed
  27. Greenberg CC, Lipsitz SR, Neville B, In H, Hevelone N, Porter SA, Weeks C, Jha AK, Gawande AA, Schrag D, Weeks JC. Receipt of appropriate surgical care for Medicare beneficiaries with cancer. Arch Surg. 2011 Oct; 146(10):1128-34.
    View in: PubMed
  28. Sher DJ, Neville BA, Chen AB, Schrag D. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e197-206.
    View in: PubMed
  29. Chen AB, Neville BA, Sher DJ, Chen K, Schrag D. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol. 2011 Jun 10; 29(17):2305-11.
    View in: PubMed
  30. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011 Nov 15; 117(22):5094-102.
    View in: PubMed
  31. Martin MY, Pisu M, Oster RA, Urmie JM, Schrag D, Huskamp HA, Lee J, Kiefe CI, Fouad MN. Racial variation in willingness to trade financial resources for life-prolonging cancer treatment. Cancer. 2011 Aug 1; 117(15):3476-84.
    View in: PubMed
  32. Yung RL, Chen K, Abel GA, Gesten FC, Roohan PJ, Boscoe FP, Sinclair AH, Schymura MJ, Schrag D. Cancer disparities in the context of Medicaid insurance: a comparison of survival for acute myeloid leukemia and Hodgkin's lymphoma by Medicaid enrollment. Oncologist. 2011; 16(8):1082-91.
    View in: PubMed
  33. Boscoe FP, Schrag D, Chen K, Roohan PJ, Schymura MJ. Building capacity to assess cancer care in the Medicaid population in New York State. Health Serv Res. 2011 Jun; 46(3):805-20.
    View in: PubMed
  34. Sima CS, Panageas KS, Schrag D. Cancer screening among patients with advanced cancer. JAMA. 2010 Oct 13; 304(14):1584-91.
    View in: PubMed
  35. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 1; 28(22):3617-22.
    View in: PubMed
  36. Chou JF, Row D, Gonen M, Liu YH, Schrag D, Weiser MR. Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study. Cancer. 2010 Jun 1; 116(11):2560-70.
    View in: PubMed
  37. Ng K, Schrag D. Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch? J Clin Oncol. 2010 Jul 10; 28(20):3207-10.
    View in: PubMed
  38. Elkin EB, Ishill NM, Snow JG, Panageas KS, Bach PB, Liberman L, Wang F, Schrag D. Geographic access and the use of screening mammography. Med Care. 2010 Apr; 48(4):349-56.
    View in: PubMed
  39. Kahn KL, Adams JL, Weeks JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefe CI, Ganz PA, Bhoopalam N, Potosky AL, Harrington DP, Fletcher RH. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010 Mar 17; 303(11):1037-45.
    View in: PubMed
  40. Jang TL, Bekelman JE, Liu Y, Bach PB, Basch EM, Elkin EB, Zelefsky MJ, Scardino PT, Begg CB, Schrag D. Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med. 2010 Mar 8; 170(5):440-50.
    View in: PubMed
  41. Sima CS, Panageas KS, Heller G, Schrag D. Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data. Appl Health Econ Health Policy. 2010; 8(1):37-51.
    View in: PubMed
  42. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009 Dec 2; 101(23):1624-32.
    View in: PubMed
  43. Gönen M, Schrag D, Weiser MR. Nodal staging score: a tool to assess adequate staging of node-negative colon cancer. J Clin Oncol. 2009 Dec 20; 27(36):6166-71.
    View in: PubMed
  44. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, Marsland TA, Michelson R, Poston GJ, Schrag D, Seidenfeld J, Benson AB. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010 Jan 20; 28(3):493-508.
    View in: PubMed
  45. Romanus D, Weiser MR, Skibber JM, Ter Veer A, Niland JC, Wilson JL, Rajput A, Wong YN, Benson AB, Shibata S, Schrag D. Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis. J Natl Compr Canc Netw. 2009 Sep; 7(8):895-904.
    View in: PubMed
  46. Greenberg CC, Ashley SW, Schrag D. Centralization of cancer surgery: what does it mean for surgical training? J Clin Oncol. 2009 Oct 1; 27(28):4637-9.
    View in: PubMed
  47. Yabroff KR, Schrag D. Challenges and opportunities for use of cost-effectiveness analysis. J Natl Cancer Inst. 2009 Sep 2; 101(17):1161-3.
    View in: PubMed
  48. Temple LK, Romanus D, Niland J, Veer AT, Weiser MR, Skibber J, Wilson J, Rajput A, Benson A, Wong YN, Schrag D. Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers. Ann Surg. 2009 Aug; 250(2):260-7.
    View in: PubMed
  49. Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009 Aug 10; 27(23):3868-74.
    View in: PubMed
  50. Yabroff KR, Warren JL, Banthin J, Schrag D, Mariotto A, Lawrence W, Meekins A, Topor M, Brown ML. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care. 2009 Jul; 47(7 Suppl 1):S64-9.
    View in: PubMed
  51. Yabroff KR, Warren JL, Schrag D, Mariotto A, Meekins A, Topor M, Brown ML. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. Med Care. 2009 Jul; 47(7 Suppl 1):S56-63.
    View in: PubMed
  52. Pham HH, Landon BE, Reschovsky JD, Wu B, Schrag D. Rapidity and modality of imaging for acute low back pain in elderly patients. Arch Intern Med. 2009 May 25; 169(10):972-81.
    View in: PubMed
  53. Ku GY, O'Reilly EM, Saltz LB, Schrag D, Maki RG, Kelsen DP, Ilson DH. Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer Invest. 2009 May; 27(4):402-6.
    View in: PubMed
  54. Phelps AC, Maciejewski PK, Nilsson M, Balboni TA, Wright AA, Paulk ME, Trice E, Schrag D, Peteet JR, Block SD, Prigerson HG. Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA. 2009 Mar 18; 301(11):1140-7.
    View in: PubMed
  55. Schrag D. Evaluating the impact of organizational changes in health care delivery: challenges in study design. J Clin Oncol. 2009 Apr 10; 27(11):1744-5.
    View in: PubMed
  56. Wideroff L, Phillips KA, Randhawa G, Ambs A, Armstrong K, Bennett CL, Brown ML, Donaldson MS, Follen M, Goldie SJ, Hiatt RA, Khoury MJ, Lewis G, McLeod HL, Piper M, Powell I, Schrag D, Schulman KA, Scott J. A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics. 2009; 12(4):233-44.
    View in: PubMed
  57. Pham HH, O'Malley AS, Bach PB, Saiontz-Martinez C, Schrag D. Primary care physicians' links to other physicians through Medicare patients: the scope of care coordination. Ann Intern Med. 2009 Feb 17; 150(4):236-42.
    View in: PubMed
  58. Schrag D, Virnig BA, Warren JL. Linking tumor registry and Medicaid claims to evaluate cancer care delivery. Health Care Financ Rev. 2009; 30(4):61-73.
    View in: PubMed
  59. Tew WP, Radovich D, O'Reilly E, Schwartz G, Schrag D, Saltz LB, Kelsen DP, Kepler S, Ilson DH. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Invest New Drugs. 2009 Aug; 27(4):366-73.
    View in: PubMed
  60. Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lepisto E, Donaldson MS, Kahn KL, Weeks JC, Ko CY, Stewart AK, Edge SB. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol. 2008 Jul 20; 26(21):3631-7.
    View in: PubMed
  61. Elkin EB, Ishill N, Riley GF, Bach PB, Gonen M, Begg CB, Schrag D. Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis. J Natl Cancer Inst. 2008 Jul 16; 100(14):1013-21.
    View in: PubMed
  62. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008 Jul 1; 113(1):57-64.
    View in: PubMed
  63. Schrag D. Enhancing cancer registry data to promote rational health system design. J Natl Cancer Inst. 2008 Mar 19; 100(6):378-9.
    View in: PubMed
  64. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008 Mar 10; 26(8):1364-70.
    View in: PubMed
  65. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008 May; 51(5):503-7.
    View in: PubMed
  66. Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008 Jan 20; 26(3):380-5.
    View in: PubMed
  67. Vickers AJ, Bianco FJ, Gonen M, Cronin AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol. 2008 May; 53(5):960-6.
    View in: PubMed
  68. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008 Feb; 51(2):147-53.
    View in: PubMed
  69. Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007 Dec 1; 25(34):5374-80.
    View in: PubMed
  70. Elkin EB, Kim SH, Casper ES, Kissane DW, Schrag D. Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions. J Clin Oncol. 2007 Nov 20; 25(33):5275-80.
    View in: PubMed
  71. Nahas CS, Shia J, Joseph R, Schrag D, Minsky BD, Weiser MR, Guillem JG, Paty PB, Klimstra DS, Tang LH, Wong WD, Temple LK. Squamous-cell carcinoma of the rectum: a rare but curable tumor. Dis Colon Rectum. 2007 Sep; 50(9):1393-400.
    View in: PubMed
  72. Bekelman JE, Zelefsky MJ, Jang TL, Basch EM, Schrag D. Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Dec 1; 69(5):1456-66.
    View in: PubMed
  73. Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007 Aug 1; 99(15):1171-7.
    View in: PubMed
  74. O'Malley AS, Pham HH, Schrag D, Wu B, Bach PB. Potentially avoidable hospitalizations for COPD and pneumonia: the role of physician and practice characteristics. Med Care. 2007 Jun; 45(6):562-70.
    View in: PubMed
  75. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007 Aug; 17(8):584-90.
    View in: PubMed
  76. Panageas KS, Schrag D, Russell Localio A, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size. Stat Med. 2007 Apr 30; 26(9):2017-35.
    View in: PubMed
  77. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007 Mar 21; 99(6):428-32.
    View in: PubMed
  78. Pham HH, Schrag D, O'Malley AS, Wu B, Bach PB. Care patterns in Medicare and their implications for pay for performance. N Engl J Med. 2007 Mar 15; 356(11):1130-9.
    View in: PubMed
  79. Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher HI, McCabe M, Schrag D. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc. 2007 May-Jun; 14(3):264-8.
    View in: PubMed
  80. Neuman HB, Schrag D, Cabral C, Weiser MR, Paty PB, Guillem JG, Minsky BD, Wong WD, Temple LK. Can differences in bowel function after surgery for rectal cancer be identified by the European Organization for Research and Treatment of Cancer quality of life instrument? Ann Surg Oncol. 2007 May; 14(5):1727-34.
    View in: PubMed
  81. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007 Jan 10; 25(2):233-7.
    View in: PubMed
  82. Ballas LK, Elkin EB, Schrag D, Minsky BD, Bach PB. Radiation therapy facilities in the United States. Int J Radiat Oncol Biol Phys. 2006 Nov 15; 66(4):1204-11.
    View in: PubMed
  83. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006 Nov; 7(11):903-9.
    View in: PubMed
  84. Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JD, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. Cancer. 2006 Oct 1; 107(7):1624-33.
    View in: PubMed
  85. Bekelman JE, Rosenzweig KE, Bach PB, Schrag D. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Oct 1; 66(2):492-9.
    View in: PubMed
  86. Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006 Jun 20; 24(18):2757-64.
    View in: PubMed
  87. Paskett ED, Schrag D, Kornblith A, Lamont EB, Weeks JC, Marshall JR, Shapiro C, Holland J. Cancer and leukemia group B cancer control and health outcomes committee: origins and accomplishments. Clin Cancer Res. 2006 Jun 1; 12(11 Pt 2):3601s-5s.
    View in: PubMed
  88. Schrag D, Xu F, Hanger M, Elkin E, Bickell NA, Bach PB. Fragmentation of care for frequently hospitalized urban residents. Med Care. 2006 Jun; 44(6):560-7.
    View in: PubMed
  89. Indurkhya A, Mitra N, Schrag D. Using propensity scores to estimate the cost-effectiveness of medical therapies. Stat Med. 2006 May 15; 25(9):1561-76.
    View in: PubMed
  90. Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006 Mar 20; 24(9):1357-62.
    View in: PubMed
  91. Schrag D, Earle C, Xu F, Panageas KS, Yabroff KR, Bristow RE, Trimble EL, Warren JL. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst. 2006 Feb 1; 98(3):163-71.
    View in: PubMed
  92. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006 Feb 1; 98(3):172-80.
    View in: PubMed
  93. Chiao EY, Krown SE, Stier EA, Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr. 2005 Dec 1; 40(4):451-5.
    View in: PubMed
  94. Jeong SY, Chessin DB, Schrag D, Riedel E, Wong WD, Guillem JG. Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2005 Nov 16; 97(22):1705-6; author reply 1706-7.
    View in: PubMed
  95. Hillner BE, Schrag D, Sargent DJ, Fuchs CS, Goldberg RM. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer. 2005 Nov 1; 104(9):1871-84.
    View in: PubMed
  96. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005 Oct 5; 97(19):1407-27.
    View in: PubMed
  97. Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer. 2005 Sep 15; 104(6):1149-57.
    View in: PubMed
  98. Schrag D. Communication and coordination: the keys to quality. J Clin Oncol. 2005 Sep 20; 23(27):6452-5.
    View in: PubMed
  99. Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst. 2005 Aug 17; 97(16):1221-4.
    View in: PubMed
  100. Dohan D, Schrag D. Using navigators to improve care of underserved patients: current practices and approaches. Cancer. 2005 Aug 15; 104(4):848-55.
    View in: PubMed
  101. Pham HH, Schrag D, Hargraves JL, Bach PB. Delivery of preventive services to older adults by primary care physicians. JAMA. 2005 Jul 27; 294(4):473-81.
    View in: PubMed
  102. Schrag D. Discussing drug costs with patients. Clin Adv Hematol Oncol. 2005 Jul; 3(7):525-6.
    View in: PubMed
  103. Temple LK, Bacik J, Savatta SG, Gottesman L, Paty PB, Weiser MR, Guillem JG, Minsky BD, Kalman M, Thaler HT, Schrag D, Wong WD. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. Dis Colon Rectum. 2005 Jul; 48(7):1353-65.
    View in: PubMed
  104. Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H, Begg CB. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005 Jun; 65(6):1118-25.
    View in: PubMed
  105. Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, Schrag D. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol. 2005 May 20; 23(15):3552-61.
    View in: PubMed
  106. Schrag D, Weiser M, Schattner M, Shia J, Akhurst T. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer. J Clin Oncol. 2005 Mar 20; 23(9):1799-802.
    View in: PubMed
  107. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005 Mar 20; 23(9):1803-10.
    View in: PubMed
  108. Bach PB, Schrag D, Begg CB. Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA. 2004 Dec 8; 292(22):2765-70.
    View in: PubMed
  109. Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004 Sep 1; 22(17):3475-84.
    View in: PubMed
  110. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. N Engl J Med. 2004 Aug 5; 351(6):575-84.
    View in: PubMed
  111. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004 Sep 1; 22(17):3631-8.
    View in: PubMed
  112. Schrag D. The price tag on progress--chemotherapy for colorectal cancer. N Engl J Med. 2004 Jul 22; 351(4):317-9.
    View in: PubMed
  113. Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, Brouwers M, Charette M, Haller DG. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004 Aug 15; 22(16):3408-19.
    View in: PubMed
  114. Basch EM, Thaler HT, Shi W, Yakren S, Schrag D. Use of information resources by patients with cancer and their companions. Cancer. 2004 Jun 1; 100(11):2476-83.
    View in: PubMed
  115. Rizk NP, Bach PB, Schrag D, Bains MS, Turnbull AD, Karpeh M, Brennan MF, Rusch VW. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004 Jan; 198(1):42-50.
    View in: PubMed
  116. Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Willett CG, MacDonald JS, Benson AB, Fuchs CS. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol. 2004 Jan 1; 22(1):166-74.
    View in: PubMed
  117. Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med. 2003 Oct 21; 139(8):649-57.
    View in: PubMed
  118. Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. The effect of clustering of outcomes on the association of procedure volume and surgical outcomes. Ann Intern Med. 2003 Oct 21; 139(8):658-65.
    View in: PubMed
  119. Schrag D, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, Begg CB. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol. 2003 Jun; 83(2):68-78; discussion 78-9.
    View in: PubMed
  120. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003 Apr 16; 95(8):588-97.
    View in: PubMed
  121. Schrag D, Panageas KS, Riedel E, Cramer LD, Guillem JG, Bach PB, Begg CB. Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg. 2002 Nov; 236(5):583-92.
    View in: PubMed
  122. Bach PB, Schrag D. Risk charts: putting cancer in context. J Natl Cancer Inst. 2002 Oct 16; 94(20):1584-5; author reply 1585-6.
    View in: PubMed
  123. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002 Oct 1; 20(19):3999-4005.
    View in: PubMed
  124. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002 Aug; 40(8 Suppl):IV-19-25.
    View in: PubMed
  125. Schrag D, Bach PB, Dahlman C, Warren JL. Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources. Med Care. 2002 Aug; 40(8 Suppl):IV-96-103.
    View in: PubMed
  126. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002 Aug; 40(8 Suppl):IV-3-18.
    View in: PubMed
  127. Begg CB, Schrag D. Attribution of deaths following cancer treatment. J Natl Cancer Inst. 2002 Jul 17; 94(14):1044-5.
    View in: PubMed
  128. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002 Apr 24; 287(16):2106-13.
    View in: PubMed
  129. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, Scardino PT. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002 Apr 11; 346(15):1138-44.
    View in: PubMed
  130. Linsley BK, Wellington GM, Schrag DP. Decadal sea surface temperature variability in the subtropical South Pacific from 1726 to 1997 A.D. Science. 2000 Nov 10; 290(5494):1145-8.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Schrag's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (394) concept(s)
_
Co-Authors
See all (60) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_